Collaborating Authors


Does this artificial intelligence think like a human?


In machine learning, understanding why a model makes certain decisions is often just as important as whether those decisions are correct. For instance, a machine-learning model might correctly predict that a skin lesion is cancerous, but it could have done so using an unrelated blip on a clinical photo. While tools exist to help experts make sense of a model's reasoning, often these methods only provide insights on one decision at a time, and each must be manually evaluated. Models are commonly trained using millions of data inputs, making it almost impossible for a human to evaluate enough decisions to identify patterns. Now, researchers at MIT and IBM Research have created a method that enables a user to aggregate, sort, and rank these individual explanations to rapidly analyze a machine-learning model's behavior.

AI for Healthcare Gets Practical as IBM sells Watson Health


At one time IBM Watson Health was featured in articles that claimed it might cure cancer. But the splashy coverage of IBM's artificial intelligence brand aimed at the healthcare industry was maybe an instance when the hype about a particular technology -- AI -- got ahead of that technology's actual capabilities. After a few high-profile public failures over the past several years, IBM has announced that it is selling the parts of its Watson Health business to private equity firm Francisco Partners -- a sale that many in the industry had expected for the past year. The assets sold include data sets and products from the many acquisitions IBM completed to roll into the Watson Health brand including Health Insights, MarketScan, Clinical Development, Social Program Management, Micromedex, and imaging software. Francisco Partners will employ key members of the Watson Health team and stand up its own business in the future, the companies said in the announcement of the deal.

Zenzium supports a new trial of wearable technologies in combination with AI for cancer patients


January 31, 2020 – Zenzium, Ltd., announced today its participation in a groundbreaking trial in Greater Manchester which is to test cutting edge wearable technology in combination with Artificial Intelligence (AI) for patients who have received cancer treatment. Called, EMBRaCE, (Enhanced Monitoring for Better Recovery and Cancer Experience), the trial is a collaboration between Manchester University NHS Foundation Trust, The Christie NHS Foundation Trust, The University of Manchester, Aptus Clinical and Zenzium, Ltd. The trial has opened initially for blood cancer, lung, and colorectal cancer patients and will run across Greater Manchester. Using commercially available health sensors and devices in combination with AI could reveal digital fingerprints associated with vital signs and other clinical data that could allow doctors to assess the progress of their patients and potentially improve patient outcomes. The technologies under investigation include: • a smart ring, worn on any finger made by Oura Health • the Withings ScanWatch, a hybrid smartwatch • the Isansys system, which is worn on the chest • AI capabilities developed and provided by Zenzium The technologies can assess a range of vital signs, including electrocardiogram (ECG), heart rate, temperature, physical activity levels and sleep.

Roche announces the release of its newest artificial intelligence based digital pathology algorithms to aid pathologists in evaluation of breast cancer markers, Ki-67, ER and PR


Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the research use only (RUO) launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for breast cancer, which are important biomarkers for breast cancer patients. Breast cancer is the second most common cancer in the world with an estimated 2.3 million new cases in 2020¹ and is the most common cancer in women globally¹,². These new algorithms complete the Roche digital pathology breast panel of image analysis algorithms. This includes a whole slide analysis workflow with automated pre-computing of the slide image prior to pathologist assessment, and a clear visual overlay highlighting tumour cells with and without nuclear staining. Intended for use with Roche's high medical value assays and slides stained on a BenchMark ULTRA instrument using ultraView DAB detection kit, the uPath Ki-67 (30-9) image analysis, uPath ER (SP1) image analysis and uPath PR (1E2) image analysis algorithms are ready-to-use and integrated within Roche's uPath enterprise software and NAVIFY Digital Pathology, the cloud version of uPath.

GE Healthcare and Optellum Join Forces to Advance Lung Cancer Diagnosis with Artificial Intelligence


GE Healthcare and Optellum today announced that they have signed a letter of intent to collaborate to advance precision diagnosis and treatment of lung cancer. GE Healthcare is a global leader in medical imaging solutions. Optellum is the leader in AI decision support for the early diagnosis and optimal treatment of lung cancer. This press release features multimedia. Together, the companies are seeking to address one of the largest challenges in the diagnosis of lung cancer, helping providers to determine the malignancy of a lung nodule: a suspicious lesion that may be benign or cancerous.

Everything announced at Nvidia's Fall GTC 2021: Omniverse Avatar, CuQuantum, Clara Holoscan and more


A synthetic camera image and corresponding ground-truth data showing instance segmentation generated by NVIDIA DRIVE Sim powered by Omniverse Replicator. Nvidia this week is showcasing how it plans to help enterprises jump into the virtual world, enabling life-like simulations and engaging avatars. Its plans for expanding Omniverse, its platform for extending workflows into the virtual sphere, were just part of several announcements delivered on Day One of Nvidia's fall Graphics Technology Conference (GTC) 2021, where the chipmaker is laying out its plans to advance accelerated computing. "A constant theme you'll see -- how Omniverse is used to simulate digital twins of warehouses, plants and factories, of physical and biological systems, the 5G edge, robots, self-driving cars, and even avatars," Nvidia CEO Jensen Huang said in prepared remarks. Underscoring the scale of Nvidia's ambitions for Omniverse, Huang said Nvidial will build a digital twin to simulate and predict climate change, E-2, or Earth Two. Along with Omniverse expansions, Nvidia announced a range of new Nvidia products and initiatives, spanning enterprise AI, cybersecurity and quantum computing, as well as advances in automotive and healthcare.

AI Pharma Deals: Bayer and AI Startups


So far, the pharmaceutical industry has contributed more to the well-being of humanity than any other industry. But lately its business model has been under significant pressure since the return on R&D investment has dropped to its lowest level in decades (lack of innovation amid digital disruption, rapid technological advances and other issues such as lack of data reproducibility) and its public reputation in US and around the world (anti vaccine movement in Europe) is worse than ever. This worrisome mix of little growth potential and low reputation is the main reason why investors are increasingly worried, not to mention that the current drug development process needs a big dose of digital innovation to deal with its messy data. As a matter of fact, Stefan Oelrich member of the Board Management of Bayer AG, President Pharmaceuticals, wrote in an article -- that the title perfectly summarises the AI pharma situation "Artificial Intelligence - When we Suddenly Know What we Don't Know" -- the following: "As we open the first doors in this unknown land we start to discover how much more is out there for our entire pharmaceutical value chain spanning from research to product supply. I expect AI to help us know what we have not known so far. Artificial Intelligence will become instrumental in our search for new medicines to better serve patients around the world as we leverage Science For A Better Life".

Could Artificial Intelligence Be About To Replace Your Doctor?


The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global healthcare industry, America is definitely not first. Americans are fed up, and a digital revolution that goes way beyond telemedicine is the only thing that will restore control. Fixing it is a highly disruptive, multi-trillion-dollar opportunity. Telemedicine, or'Telehealth', will soar from $42 billion in 2018 to $400 billion in 2026. Healthcare IT alone will be worth $390 billion by 2024.

A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector


A massive disruption now appears imminent in one of the world's largest – and most important – industries. In much the same way that Amazon disrupted the retail business – and how PayPal disrupted the payments industry – one under-the-radar health technology company now seeks to transform the $11.85 trillion global health industry. By moving healthcare away from brick and mortar, traditional medicine into an AI-driven tool that offers unprecedented speed, efficiency, and accuracy... Investors still have a brief window of opportunity to get in on this transformational investment opportunity while it still flies beneath Wall Street's radar. But as you'll soon discover, this company's technology is so powerful that it could become a valuable addition to hundreds of millions of households worldwide. Whether most patients, providers, or large healthcare companies realize it or not, the healthcare industry is already in the early stages of significant change. That's because patients now desire access to more information – and better information – in the blink of an eye. In a recent survey of U.S. health consumers, 71% reported facing major frustrations through their experience with healthcare providers. Concerns ranged from difficulties scheduling appointments to impersonal visits.

Paige Receives First Ever FDA Approval for AI Product in Digital Pathology


NEW YORK--(BUSINESS WIRE)--Paige, the global leader in AI-based diagnostic software in pathology, today announced that the U.S. Food and Drug Administration (FDA) has granted de novo marketing authorization for Paige Prostate, a clinical-grade AI solution for prostate cancer detection. As a novel technology, Paige Prostate is the first AI-based pathology product to receive de novo approval from the FDA, allowing in vitro diagnostic (IVD) use via Paige's FDA-cleared FullFocus digital pathology viewer. With a projected 60 percent increase in the number of cancer cases globally in the next two decades and a decrease in the number of pathologists relative to this diagnostic demand, there is a significant need to provide new technologies for the practice of pathology. Paige Prostate is a cancer detection solution that identifies foci suspicious for cancer and provides this information to the pathologist. Paige Prostate is designed to assist pathologists in finding small foci of cancer and enable pathologists to work efficiently and confidently in their diagnostic process.